Trial to Evaluate Endoscopic Duodenal PEF Therapy with Semaglutide for Insulin-Dependent Type 2 Diabetes
Background
Type 2 Diabetes Mellitus (T2DM), particularly in its insulin-dependent forms, remains a significant challenge, often necessitating intensive insulin regimens with associated risks. While current therapies, including GLP-1 receptor agonists like semaglutide, effectively improve glycemic control, they may not fully address underlying gut-related metabolic dysfunction. Duodenal mucosal abnormalities are increasingly recognized as contributors to T2DM pathogenesis. Endoscopic duodenal therapies, such as pulsed electric field (PEF) ablation, aim to regenerate the duodenal mucosa, potentially enhancing insulin sensitivity and glucose homeostasis. Combining these distinct approaches could offer synergistic benefits for T2DM management.
Study Design
The planned study aims to evaluate the safety, feasibility, and efficacy of endoscopic duodenal pulsed electric field (PEF) therapy, utilizing the Endogenex System en Gen 2 Device, combined with a GLP-1 receptor agonist (Semaglutide, Ozempic). The target population for this investigation is subjects diagnosed with insulin-dependent type 2 diabetes mellitus. Primary endpoints are expected to encompass safety assessments (e.g., adverse events), the feasibility of performing the endoscopic procedure, and efficacy measures related to improvements in glycemic control.
Why It Matters
If successful, this combined therapeutic strategy could represent a novel, potentially disease-modifying approach for individuals with insulin-dependent Type 2 Diabetes. It signifies a shift beyond purely pharmacological management by addressing underlying gut-level pathology. For clinicians, it could introduce an endoscopic intervention as a standard adjunct to existing GLP-1 agonist therapies. For patients, this approach might offer a pathway to reduced insulin dependence and improved long-term glycemic control. The envisioned protocol would involve a one-time or infrequent endoscopic procedure integrated with ongoing semaglutide therapy, marking a significant evolution in T2DM management strategies.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
semaglutide
type 2 diabetes
endoscopic therapy
glp-1 agonist
clinical trial
duodenal regeneration
